Motus gi receives fda clearance to market the pure-vu® system for upper gi endoscopy

Fort lauderdale, fla., april 30, 2021 (globe newswire) -- motus gi holdings, inc., (nasdaq: mots) ("motus gi" or the "company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that it has received 510(k) clearance from the u.s. food and drug administration (“fda”) for a version of the pure-vu® system that is compatible with gastroscopes used during upper gastrointestinal (gi) endoscopy procedures to remove blood, blood clots and debris in order to provide a clear field-of-view for the endoscopist. this proprietary technology is the latest innovation for the pure-vu system platform that is specifically designed to integrate with therapeutic gastroscopes to enable safe and rapid cleansing during the procedure, while preserving established procedural workflow and techniques.
MOTS Ratings Summary
MOTS Quant Ranking